UY33923A - Combinación antitumoral que comprende cabazitaxel y cisplatino - Google Patents

Combinación antitumoral que comprende cabazitaxel y cisplatino

Info

Publication number
UY33923A
UY33923A UY0001033923A UY33923A UY33923A UY 33923 A UY33923 A UY 33923A UY 0001033923 A UY0001033923 A UY 0001033923A UY 33923 A UY33923 A UY 33923A UY 33923 A UY33923 A UY 33923A
Authority
UY
Uruguay
Prior art keywords
cabazitaxel
cisplatin
antitumor combination
antitumor
combination
Prior art date
Application number
UY0001033923A
Other languages
English (en)
Inventor
Patricia Vrignaud
Bissery Marie-Christine
Dedieu Jean-Francois
Akbar Khan
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45774193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11305204A external-priority patent/EP2491925A1/en
Priority claimed from EP12305109.6A external-priority patent/EP2620148A1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY33923A publication Critical patent/UY33923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una combinación que comprende cabazitaxel y cisplatino. La presente invención también se refiere a una composición farmacéutica que contiene dicha combinación y a un kit farmacéutico que comprende: (i) una primera formulación galénica que comprende cabazitaxel; y (ii) una segunda formulación galénica que comprende cisplatino. La invención también se refiere al uso de esta combinación y/o composición farmacéutica y/o kit farmacéutico en el tratamiento de enfermedades neoplásicas, más particularmente en el tratamiento del cáncer.
UY0001033923A 2011-02-25 2012-02-24 Combinación antitumoral que comprende cabazitaxel y cisplatino UY33923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305204A EP2491925A1 (en) 2011-02-25 2011-02-25 Antitumoral combination comprising cabazitaxel and cisplatin
EP12305109.6A EP2620148A1 (en) 2012-01-27 2012-01-27 Antitumoral combination comprising cabazitaxel and cisplatin

Publications (1)

Publication Number Publication Date
UY33923A true UY33923A (es) 2012-09-28

Family

ID=45774193

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033923A UY33923A (es) 2011-02-25 2012-02-24 Combinación antitumoral que comprende cabazitaxel y cisplatino

Country Status (15)

Country Link
US (2) US20140056996A1 (es)
EP (1) EP2678011B1 (es)
AR (1) AR085399A1 (es)
CY (1) CY1122357T1 (es)
DK (1) DK2678011T3 (es)
ES (1) ES2745506T3 (es)
HR (1) HRP20191322T1 (es)
HU (1) HUE046232T2 (es)
LT (1) LT2678011T (es)
PL (1) PL2678011T3 (es)
PT (1) PT2678011T (es)
SI (1) SI2678011T1 (es)
TW (1) TWI598097B (es)
UY (1) UY33923A (es)
WO (1) WO2012113897A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
TW201540296A (zh) * 2014-01-13 2015-11-01 Aventis Pharma Sa 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途
CN110384679A (zh) * 2018-04-16 2019-10-29 广州铠宝蕊医药科技有限公司 卡巴他赛白蛋白纳米粒制剂及其制备方法与应用
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co Ltd FORMULATIONS OF CABAZITAXEL

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
ATE302685T1 (de) 2003-07-02 2005-09-15 Scheuten Glasgroep Bv Verfahren zur herstellung einer brandschutzverglasung
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine

Also Published As

Publication number Publication date
SI2678011T1 (sl) 2019-09-30
WO2012113897A1 (en) 2012-08-30
CY1122357T1 (el) 2021-01-27
HUE046232T2 (hu) 2020-02-28
EP2678011B1 (en) 2019-06-26
US20180153931A1 (en) 2018-06-07
EP2678011A1 (en) 2014-01-01
DK2678011T3 (da) 2019-09-23
PL2678011T3 (pl) 2019-12-31
AR085399A1 (es) 2013-09-25
PT2678011T (pt) 2019-09-26
LT2678011T (lt) 2019-12-10
ES2745506T3 (es) 2020-03-02
HRP20191322T1 (hr) 2019-10-18
TW201249435A (en) 2012-12-16
TWI598097B (zh) 2017-09-11
US20140056996A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
UY34374A (es) Benzilindazoles sustituidos
UY34550A (es) Bencilpirazoles sustituidos
UY4169Q (es) Altoparlante
MX2019008211A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34034A (es) Triazolopiridinas
UY34765A (es) Compuestos novedosos.
UY34817A (es) Tienopirimidinas
UY34515A (es) Triazolopiridinas sustituidas
EA201400178A1 (ru) Лечение рака молочной железы
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34006A (es) Imidazopiridazinas
UY4281Q (es) Juguera
UY34329A (es) Compuestos de triazolopiridina
UY33976A (es) Derivados de pirazolo-pirimidina.
UY4181Q (es) Taza
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida
UY34677A (es) Imidazopiridazinas sustituidas
UY33923A (es) Combinación antitumoral que comprende cabazitaxel y cisplatino
UY34753A (es) Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
UY34596A (es) "engrasado"
UY4241Q (es) Mesa
UY34081A (es) Composición farmacéutica que comprende drotaverina
UY33953A (es) Triazina-oxadiazoles
UY34232A (es) Combinación antitumoral que comprende ombrabulina y cisplatino,asociada a radioterapia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019